Optimized Fc Variants
AssigneeXencor, Inc.
InventorsBassil I. Dahiyat, Gregory A. Lazar, Omid Vafa
Life of this patent
Estimating the term…
Abstract
The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
Claims9
A method of enhancing macrophage activation comprising administering to a patient an anti-CD20 antibody comprising an Fc variant of the human Fc polypeptide comprising SEQ ID NO:1, wherein said Fc variant portion comprises at least one substitution at a position corresponding to the position of SEQ ID NO:1 selected from the group consisting of positions 234, 235, 239, 240, 241, 243, 244, 245, 247, 262, 263, 264, 265, 266, 267, 269, 296, 297, 298, 299, 313, 325, 326, 327, 328, 329, 330, 332, 333, and 334, wherein said Fc variant enhances macrophage activation as compared to the unsubstituted Fc variant.
Dependencies are inferred from the claim text.